The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange ...

Citing four unnamed people "familiar with the situation," this effort will be based on findings that were apparently filed with the federal government's Vaccine Adverse Event Reporting System. The ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

BioNTech (NASDAQ:BNTX) is preparing to release its quarterly earnings on Monday, 2025-11-03. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Friday afternoon, a ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...

Robeco Institutional Asset Management B.V. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 23.5% in the first quarter, according to the company in its most recent ...

A key enabler for BioNTech's ambitious plans is an exceptionally strong balance sheet, rare for a biotechnology company. As of the end of 2025, the Mainz-based firm reported liquid funds of ...